Early recovery of host-derived hematopoiesis in marrow transplant recipients conditioned with high-dose busulfan and cyclophosphamide

Bone Marrow Transplant. 1995 May;15(5):787-9.

Abstract

Three marrow transplant recipients with hematologic malignancies (two AML, one myelodysplastic syndrome) experienced prolonged pancytopenia after allogeneic BMT following conditioning with non-TBI regimens containing high-dose busulfan and cyclophosphamide (Bu/CY), despite the use of G-CSF. Early recovery of host-derived hematopoiesis ensued. Although neutrophil counts in these patients exceeded 500 x 10(6)/l by day 30 after transplant, these cells were of host origin. This early recovery of host-derived hematopoiesis has been observed rarely among patients conditioned with TBI-based regimens. When patients conditioned with Bu/CY show delayed hematologic recovery, mixed chimerism should be considered even in the presence of normal neutrophil recovery.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Bone Marrow Transplantation*
  • Busulfan / therapeutic use*
  • Child, Preschool
  • Combined Modality Therapy
  • Cyclophosphamide / therapeutic use*
  • Female
  • Hematopoiesis*
  • Humans
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Myelodysplastic Syndromes / therapy*
  • Time Factors
  • Whole-Body Irradiation*

Substances

  • Cyclophosphamide
  • Busulfan